Autophagy in Heart Failure: Insights into Mechanisms and Therapeutic Implications

Magdalena Bielawska1, Marta Warszyńska1, Monika Stefańska1

  • 1Department of Clinical Immunology, Jagiellonian University Medical College, University Children's Hospital, Wielicka 265, 30-663 Cracow, Poland.

Insights

Autophagy is vital for heart health, acting as a cellular cleanup process that combats heart failure. Understanding its role and therapeutic potential is key for future treatments.

Area of Science:

  • Cardiovascular Biology
  • Cellular Biology
  • Molecular Medicine

Background:

  • Autophagy is a critical cellular process for clearing damaged components and maintaining heart function.
  • In heart failure, autophagy acts as a protective mechanism against disease progression.
  • Its significance is established in both animal models and human heart studies.

Purpose of the Study:

  • To review the role of autophagy in heart failure progression.
  • To consolidate current knowledge on autophagy deregulation in heart failure.
  • To explore the therapeutic potential of targeting autophagy.

Main Methods:

  • Comprehensive review of published data on autophagy in heart failure.
  • Analysis of genetic and pharmacological interventions affecting autophagy.
  • Examination of autophagy's molecular mechanisms in cardiomyocytes, cardiac fibroblasts, and endothelial cells.

Main Results:

  • Autophagy deregulation, through genetic or pharmacological means, impacts ischemic and non-ischemic heart failure models.
  • Autophagy influences key cellular processes in cardiomyocytes, cardiac fibroblasts, and endothelial cells.
  • Current research highlights the complex involvement of autophagy in heart failure pathophysiology.

Conclusions:

  • Autophagy plays a dual role in heart failure, potentially protective or detrimental depending on context.
  • Further research is needed to fully elucidate the therapeutic strategies targeting autophagy for heart failure.
  • Targeting autophagy holds promise for novel heart failure management approaches.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
621